Research & Industry Updates
Research & Industry Updates
Stay informed.
Stay structured.
Curated research developments, regulatory changes, and market trends — with sources linked so you can read further yourself.
Editorial note: All content is presented for general educational and informational purposes only. Nothing here constitutes medical advice, investment guidance, or product endorsement. All claims are sourced and linked. Stratik Performance Labs does not sell peptide compounds of any kind.
Major shift: 14 restricted peptides expected to return to compounding status
In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed on the FDA's Category 2 restricted list are expected to move back to legal compounding status. This would allow licensed compounding pharmacies under physician supervision to once again prepare compounds including BPC-157, CJC-1295, AOD-9604, Selank, Semax, and KPV for patients with valid prescriptions. The announcement does not change the legal status of unauthorized online sales — research-use positioning and prescription requirements remain in effect.
FDA enforces revised compounding restrictions — Category 2 list takes effect
From January 2025, the FDA began enforcing revisions to its interim policy on bulk drug substances used by compounding pharmacies. The move restricted 19 commonly discussed peptides — including BPC-157, TB-500, and Ipamorelin — from being compounded without further regulatory review. The policy shift ended years of regulatory tolerance and elevated the importance of formal drug development pathways for peptide compounds.
Health Canada maintains warnings on unauthorized injectable peptides
Health Canada continues to classify most synthetic injectable peptides as prescription drugs under the Food and Drugs Act. The agency has issued specific advisory warnings naming compounds including BPC-157, TB-500, CJC-1295, Ipamorelin, and Retatrutide — cautioning Canadians against purchasing these products from online vendors. Health Canada's position is clear: unauthorized injectable peptides have not been assessed for safety, efficacy, or quality. Labels reading "For Research Use Only" do not make these products legal for human use in Canada.
GLP-1 drugs expand beyond diabetes — cardiovascular approval and generic access mark new era
Semaglutide received FDA approval in March 2024 for cardiovascular risk reduction in overweight adults with established heart disease. Tirzepatide became the world's best-selling drug by Q3 2025 with $10.1 billion in a single quarter. As of late 2025, approximately 1 in 8 US adults (12.4%) reported taking a GLP-1 drug — double the rate from 18 months prior. The FDA approved the first generic GLP-1 (liraglutide) in August 2025, marking the beginning of a broader access era for peptide-based metabolic medicine.
BPC-157 systematic review: 544 papers screened, evidence base remains predominantly preclinical
A 2025 systematic review screened 544 BPC-157 papers — of the 36 that met inclusion criteria, 35 were rodent or cell-based studies, with only one involving humans in a musculoskeletal context. The review confirmed research signals in angiogenesis, growth-factor signalling, and musculoskeletal healing, while emphasizing the significant gap between preclinical promise and human clinical evidence. A randomized, double-blind, placebo-controlled human trial has since been registered — the kind of rigorous study needed to meaningfully advance the evidence base.
Retatrutide Phase 3 trials underway — triple agonist generates significant research interest
Retatrutide, a novel triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, is currently in Phase 3 clinical trials as of 2025–2026. Early phase data showed notable outcomes in metabolic research. Pharmaceutical analysts have noted that gray-market marketing of Retatrutide has significantly outpaced verified clinical data — a common pattern in the research peptide space. Not approved for any use.
2025 meta-analysis supports collagen peptide supplementation for bone and muscle health
A 2025 meta-analysis found that collagen peptide supplementation may improve bone mineral density and muscle function — one of the stronger human-evidence findings in the broader peptide wellness space. Collagen peptides occupy a unique regulatory position as naturally occurring food-supply compounds, making them eligible for supplement marketing under existing frameworks. This distinguishes them significantly from synthetic research peptides, which face much stricter regulatory scrutiny.
Global peptide pipeline: 1,200+ candidates in active trials — AI-driven discovery accelerating development
Over 1,200 peptide molecules are currently in active clinical development worldwide, with metabolic disease and oncology leading the research pipeline. The FDA granted 47 peptide candidates orphan drug status in 2024 alone. AI-driven peptide discovery is increasingly being applied to identify novel compounds, with pharmaceutical companies reporting shorter development timelines. The global peptide therapeutics market is projected to grow from $52.6 billion in 2025 to approximately $87–102 billion by 2035.
Temperature consistency
Freeze-thaw cycles degrade peptide structure. Consistent refrigeration (2–8°C) is the research standard for most reconstituted compounds.
Lyophilized stability
Dry (lyophilized) peptides are significantly more stable than reconstituted forms. Proper sealed storage extends usable research windows.
Light protection
UV exposure degrades many peptide compounds. Opaque, light-blocking containers are standard in research-grade storage protocols.
COA documentation
Research-grade materials should come with Certificates of Analysis (COA). Storage conditions noted on COAs should be followed precisely.
Explore our research library.
Visit the Peptide Information Hub for detailed compound profiles, evidence breakdowns, and educational overviews of the most discussed research compounds.
Peptide Information Hub →